Filing Flows › Health Care › Airsculpt Technologies (AIRS)
Airsculpt Technologies (AIRS) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 6, 2026 · Airsculpt Technologies (AIRS) Q3 2026 earnings results →
Q3 2026 Revenue down 9% year over year to $31.9M · 22¢ of every $1 of revenue lost · operating margin -13.0%
Airsculpt Technologies made $31.9M in Q3 2026 (-9% Y/Y). Operating margin -13.0%, net loss $7.2M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 6, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $31.9M in Q3 2026, down 9% year over year and down 26% from the previous quarter.
Operating costs exceeded revenue by $4.1M, an operating margin of -13.0%. Total costs fell 19% while revenue fell 9%. The quarter ended with a net loss of $7.2M, wider than the previous quarter's $1.1M loss.
Operating cash flow was −$3.5M. Non-cash charges added back $2.9M of depreciation and amortization and $1.1M of share-based compensation. Working capital and other items used $299K. Capital expenditures of $226K exceeded it, leaving free cash flow of −$3.7M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 6, 2026 | $31.9M | -9% | -13.0% | −$7.2M | −$3.5M |
| Q2 2026 | 10-Q | Aug 10, 2026 | $42.9M | -2% | -0.1% | −$1.1M | −$1.2M |
| Q1 2026 | 10-Q | May 8, 2026 | $39.4M | 0% | -4.6% | −$2.4M | $5.3M |
| Q4 2025 | 10-K | Mar 31, 2026 | $33.4M | -15% | -3.0% | $1.3M | −$2.5M |
| Q3 2025 | 10-Q | Nov 7, 2025 | $35.0M | -18% | -27.9% | −$9.5M | −$225K |
| Q2 2025 | 10-Q | Aug 1, 2025 | $44.0M | -14% | 1.8% | −$591K | $5.0M |
| Q1 2025 | 10-Q | May 2, 2025 | $39.4M | -17% | -4.0% | −$2.8M | $868K |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Airsculpt Technologies
Unless otherwise indicated or the context otherwise requires, references in this Annual Report on Form 10-K to the “Company,” “AirSculpt,” “we,” “us” and “our” refer to AirSculpt Technologies, Inc. and its consolidated subsidiaries and the Professional Associations (as defined hereinafter). AirSculpt is a next-generation body contouring treatment designed to optimize both comfort and precision, available exclusively at AirSculpt offices. The minimally invasive procedure removes fat and tightens skin, while sculpting targeted areas of the body, allowing for quick healing with minimal bruising, tighter skin, and precise results.
In its own words, from its 10-K, filed Mar 31, 2026.
Airsculpt Technologies against its Services-Offices & Clinics of Doctors of Medicine peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -9% against the peers' median -3%. Operating margin: -13.0% against the peers' median -12.9%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| AIRS Airsculpt Technologies | Q3 2026 | $31.9M | -9% | -13.0% |
| HIMS Hims & Hers Health | Q2 2026 | $753M | +38% | -12.9% |
| TDOC Teladoc Health | Q3 2026 | $605M | -3% | -4.6% |
| STLN Starling Oncology | Q3 2026 | $170M | +24% | -1.8% |
| SBC SBC Medical Group Holdings | Q2 2026 | $49.2M | +13% | 38.5% |
| LFMD LifeMD | Q2 2026 | $47.3M | -4% | -15.1% |
| CDIX Cardiff Lexington | Q2 2026 | $2.2M | -23% | -25.2% |
| HLYK HealthLynked | Q2 2026 | $250K | -58% | -215.7% |
Source: Airsculpt Technologies 10-Q on SEC EDGAR · CIK 1870940 · Services-Offices & Clinics of Doctors of Medicine
Guidance and outlook
13F: who owns AIRS and who is buying
More on AIRS
- How Airsculpt Technologies makes money: revenue by segment
- Airsculpt Technologies next earnings date and what analysts expect
- Airsculpt Technologies stock forecast, price target and fair value
- Who owns Airsculpt Technologies stock: holders, funds and Congress trades
- Airsculpt Technologies guidance and outlook
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results